Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations
The Company is completing analysis from this Phase 3 clinical trial and expects to present additional information in the second quarter of 2021.
- The Company is completing analysis from this Phase 3 clinical trial and expects to present additional information in the second quarter of 2021.
- The Company anticipates initial results from the primary endpoint of relapse-free survival at 12 months in the second quarter of 2021.
- Research and Development (R&D) expenses:R&D expenses were$9.3 millionfor the quarter endedDecember 31, 2020, compared to$8.0 millionfor the comparable period in 2019.
- General and Administrative (G&A) expenses:G&A expenses were$4.9 millionfor the quarter endedDecember 31, 2020, compared to$3.9 millionfor the comparable period in 2019.